What is the appropriate sliding‑scale regular insulin regimen for an adult inpatient who is NPO, and how should it be adjusted for renal impairment, elderly patients, pregnancy, and type 1 diabetes?

Sliding Scale Insulin for NPO Patients: Evidence-Based Recommendations

Sliding scale insulin (SSI) alone should NOT be used for NPO patients with established diabetes—instead, use a basal-plus regimen consisting of basal insulin (0.1-0.25 U/kg/day) with correctional insulin every 6 hours. 1

Understanding the Problem with Sliding Scale Insulin Alone

The 2022 Endocrine Society guidelines explicitly define SSI as a "reactive approach" that treats hyperglycemia after it occurs, without regard to nutritional status or individual insulin sensitivity 1. The 2021 Lancet Diabetes & Endocrinology guideline states that SSI use "is associated with clinically significant hyperglycemia in many patients and its use has been discouraged" 2. Research confirms SSI is ineffective, with only 6% of patients achieving good glycemic control and 84% remaining hyperglycemic despite treatment 3.

The Recommended Approach: Basal-Plus Regimen

For NPO patients, the basal-plus approach is superior:

• Basal insulin dose: 0.1-0.25 U/kg/day given once or twice daily
• Correctional insulin: Rapid-acting insulin every 6 hours based on point-of-care glucose readings
• Target glucose: 100-180 mg/dL (5.6-10.0 mmol/L) 1

This regimen provides continuous basal coverage for hepatic gluconeogenesis while allowing correction of elevated glucose levels without the meal-related bolus component 2.

Special Population Adjustments

Renal Impairment (CKD Stage ≥3, eGFR <60 mL/min/1.73 m²)

• Use lower end of dosing range (0.1 U/kg/day for basal)
• These patients are at high risk for hypoglycemia 1
• Consider 20% dose reduction if previously on higher insulin doses 2

Elderly Patients (≥65 years)

• Use conservative dosing at lower end of range
• High-risk population for hypoglycemia 1
• Target may be liberalized toward upper end of 100-180 mg/dL range

Type 1 Diabetes

• NEVER use SSI alone—this is explicitly contraindicated 2
• Must continue scheduled basal insulin even when NPO 1
• Reduce basal dose by 10-20% if previously on basal-heavy regimens (≥0.6 U/kg/day) 1
• Add correctional insulin every 6 hours
• Complete insulin cessation risks diabetic ketoacidosis

Pregnancy

• Insulin is the preferred agent for glucose management in pregnancy 4
• Use physiologic basal-bolus approach adapted for NPO status
• Tighter glycemic targets may be needed (consult obstetric guidelines)
• Rapid-acting insulin analogs are safe in pregnancy 4

Critical Implementation Details

For insulin-naive patients or those on low-dose insulin:

• Start with total daily dose 0.3-0.5 U/kg
• Allocate 50% to basal, 50% to correctional doses divided across the day 2

For patients previously on insulin ≥0.6 U/kg/day:

• Reduce total daily dose by 20% to prevent hypoglycemia 2, 1
• Redistribute with emphasis on basal component

Monitoring frequency:

• Check glucose every 4-6 hours when NPO 1
• More frequent if hypoglycemia risk is high

When to Escalate Therapy

Add scheduled insulin therapy if:

• ≥2 glucose measurements ≥180 mg/dL in 24 hours on correctional insulin alone 1
• Persistent hyperglycemia despite adequate correctional doses

Common Pitfalls to Avoid

1. Never use SSI alone in Type 1 diabetes—this can precipitate DKA 2
2. Don't continue home insulin doses unchanged—reduce by 10-20% for basal-heavy regimens 1
3. Avoid premixed insulins (70/30)—associated with unacceptably high hypoglycemia rates 2
4. Don't use SSI in patients with known diabetes requiring insulin—they need scheduled basal coverage 2, 1

The Only Acceptable Use of SSI Alone

SSI alone may be appropriate only for:

• Patients without prior diabetes with mild stress hyperglycemia 2
• Initial therapy in non-insulin-treated Type 2 diabetes with glucose >140 mg/dL 1

Even in these cases, escalate to scheduled insulin if hyperglycemia persists.

Hypoglycemia Risk Context

While basal-bolus approaches carry 4-6 times higher hypoglycemia risk than SSI 2, this reflects the fact that SSI fails to control glucose effectively. The basal-plus approach for NPO patients uses lower doses than full basal-bolus, balancing efficacy with safety. The key is appropriate dose reduction in high-risk populations (elderly, renal impairment, low BMI ≤27 kg/m²) 1.